JP2018512415A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512415A5
JP2018512415A5 JP2017550117A JP2017550117A JP2018512415A5 JP 2018512415 A5 JP2018512415 A5 JP 2018512415A5 JP 2017550117 A JP2017550117 A JP 2017550117A JP 2017550117 A JP2017550117 A JP 2017550117A JP 2018512415 A5 JP2018512415 A5 JP 2018512415A5
Authority
JP
Japan
Prior art keywords
cysteine
tercalcetide
seq
iii
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512415A (ja
JP6783787B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024308 external-priority patent/WO2016154580A1/en
Publication of JP2018512415A publication Critical patent/JP2018512415A/ja
Publication of JP2018512415A5 publication Critical patent/JP2018512415A5/ja
Application granted granted Critical
Publication of JP6783787B2 publication Critical patent/JP6783787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550117A 2015-03-26 2016-03-25 エテルカルセチドの調製のための液相方法 Active JP6783787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138903P 2015-03-26 2015-03-26
US62/138,903 2015-03-26
PCT/US2016/024308 WO2016154580A1 (en) 2015-03-26 2016-03-25 Solution phase method for preparing etelcalcetide

Publications (3)

Publication Number Publication Date
JP2018512415A JP2018512415A (ja) 2018-05-17
JP2018512415A5 true JP2018512415A5 (enExample) 2019-05-09
JP6783787B2 JP6783787B2 (ja) 2020-11-11

Family

ID=55911037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550117A Active JP6783787B2 (ja) 2015-03-26 2016-03-25 エテルカルセチドの調製のための液相方法

Country Status (7)

Country Link
US (1) US10858389B2 (enExample)
EP (1) EP3274360B1 (enExample)
JP (1) JP6783787B2 (enExample)
AU (1) AU2016238233B2 (enExample)
CA (1) CA2980960C (enExample)
ES (1) ES2806200T3 (enExample)
WO (1) WO2016154580A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN108101959B (zh) * 2016-11-24 2021-07-09 四川科伦药物研究院有限公司 一种制备高纯度多肽或其类似物的方法
CN106967155B (zh) * 2017-03-17 2018-05-15 兰州凯博药业股份有限公司 一种多肽液相合成缩宫素的方法
CN110498835B (zh) * 2018-05-17 2021-06-08 深圳翰宇药业股份有限公司 一种合成etelcalcetide的方法
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides
CN109280078B (zh) * 2018-10-30 2019-06-25 成都诺和晟泰生物科技有限公司 一种制备维拉卡肽的方法
CN109734778A (zh) * 2019-03-07 2019-05-10 苏州科技大学 一种维拉卡肽的制备方法
CN112175042B (zh) * 2019-07-03 2022-05-31 深圳翰宇药业股份有限公司 Etelcalcetide的合成方法
WO2021038431A1 (en) 2019-08-26 2021-03-04 Auro Peptides Ltd An improved process for the preparation of etelcalcetide hydrochloride
CN112521450A (zh) * 2019-09-19 2021-03-19 深圳市健翔生物制药有限公司 一种固液相结合制备维拉卡肽的方法
CN110668984B (zh) * 2019-12-03 2020-04-10 凯莱英医药集团（天津）股份有限公司 一种依特卡肽中间体及依特卡肽的合成方法
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
EP4204434A1 (en) 2020-08-31 2023-07-05 USV Private Limited An improved process for fmoc synthesis of etelcalcetide
WO2026002733A1 (en) * 2024-06-24 2026-01-02 Fresenius Kabi Ipsum S.R.L. Method for the synthesis of a peptide with amino acids having basic side-chains
CN120699096B (zh) * 2025-07-07 2026-01-23 苏州天马医药集团天吉生物制药有限公司 一种依特卡肽的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4738683B2 (ja) * 1999-07-19 2011-08-03 ジーイー・ヘルスケア・アクスイェ・セルスカプ 保護されたチオールを脱保護する方法
WO2009152850A1 (en) 2008-06-17 2009-12-23 Solvay (Société Anonyme) Peptide manufacturing process
ES2729051T3 (es) 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
WO2012068187A1 (en) 2010-11-19 2012-05-24 Merck Sharp & Dohme Corp. Poly(amide) polymers for the delivery of oligonucleotides
CA2916222C (en) * 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide

Similar Documents

Publication Publication Date Title
JP2018512415A5 (enExample)
USD861779S1 (en) Typeface
JP2017137500A5 (enExample)
JP2010518805A5 (enExample)
JP2018100276A5 (enExample)
JP2013173781A5 (enExample)
JP2017519346A5 (enExample)
USD761900S1 (en) Typeface
JP2014028813A5 (enExample)
JP2019089762A5 (enExample)
JP2018150298A5 (enExample)
JP2019502357A5 (enExample)
IN2015DN01331A (enExample)
WO2018101663A3 (ko) 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법
WO2016044445A3 (en) sGC STIMULATORS
FR3021346B1 (fr) Element de construction pour la realisation d'un tunnel, tunnel comprenant un tel element et procedes de fabrication d'un tel element et d'un tel tunnel
JP2016038993A5 (enExample)
DK3402785T3 (da) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
JP2017092104A5 (enExample)
FR3002877B1 (fr) Procede de fabrication d'un materiau composite multicouche, materiau composite multicouche obtenu par le procede et pieces ou structures mecaniques realisees avec ledit materiau.
CO2017000010A2 (es) Proceso para la preparacion de ácidos 3-hidroxipicolínicos
FR3018525B1 (fr) Alliage a base nickel a durcissement structural, piece en cet alliage et son procede de fabrication.
JP2018128902A5 (enExample)
JP2017157543A5 (enExample)
WO2016181204A8 (en) Method of making a mercury based compound, mercury based compound, methods of using the mercury based compound and uses of the mercury based compound